About us

Immunor AS is a Norwegian-based vaccine developer unlike any other. Building on comprehensively patented IP of unique elegance and power, Immunor AS is in consequence capable of great agility and precision – hence safety – in its vaccine designs.  Its core Mode of Action was most recently and sensationally validated during the Covid pandemic.  Originally formed as a diagnostics company in the mid-1980s, Immunor AS as it is today is the result of more than 25 years’ experience in the development of peptide-based vaccine technologies built on the Immunor CPSPVP (Cell Penetrating Selective Peptide Vaccine Platform) which provides a uniquely powerful platform for safe and efficacious vaccines.

What distinguishes Immunor’s offering from other traditional and new platforms such as Adenovirus and mRNA vectors is the design principle which underpins the CPSPVP.  The CPSPVP Mode of Action is of a unique molecular peptide vaccine platform created through the use of an array of sequential numerical analyses and whose antigen designs are informed by a correct understanding of the highly singular etiologies of the relevant viruses.  Immunor is partnering with Norway’s world-class centre for quantum molecular sciences in Tromso to boost its analytic capabilities.

Immunor’s platform has cracked the triple challenges of down-selection, identification, and cell penetration of and by epitopes. The Immunor CPSPVP platform has been clinically tested and validated as safe and efficacious. Furthermore, as recent research micro-genotyping cancers reveals the multiple lineages within every single patient for the first time, the premium on treatments which can enable the innate immune system to track mutations and empower its autonomous abilities in ‘personalised’ therapies, rises. With breakthrough cutting power, Immunor’s CPSPVP and the repertoire of vaccines which it can support, including cancer vaccines, stands at this leading edge.

Immunor is now poised to deliver interventions for diseases with immense world-wide demand leading with diabetic, cancer and HIV product candidates: 

  • The first step towards a cure for Diabetes Type 1 (T1D). A vaccine candidate derived from Coxsackie virus antigens (Vacc-Diab1) both prevents the destruction of insulin-producing beta-cells as a therapy as well as a T1D preventative vaccine.
  • A neuropathy and wound-healing drug for Diabetes Type 2 (T2D). This neuropathy-wound healing (NWH) drug candidate addresses T2D long-term side-effects including neuropathy, ulcers, and lower extremity amputations
  • The CPSPVP as an onco-viral cancer vaccine platform has been refined during more than 10 years research, most specifically into an onco-viral vaccine (Vacc-Ct1) derived from the Human Herpes Virus 5, Cytomegalovirus (CMV) antigens. This specialized platform carries antigens critical for development of various cancer forms including Glioblastoma (brain cancer), breast cancer and other CMV- driven cancer forms, including other Human Herpes oncogenic viruses such as Epstein Barr – Human Herpes Virus 4.
  • The world’s first working HIV vaccine (Vacc-45). This market space re-opened in early 2023 following the failure of the fourth major HIV prevention trial in thirty years

An HIV entry inhibitor drug candidate (CRX), which will facilitate the development of a functional cure for HIV in combination with Vacc-45


  • 7th February 2023. Upon invitation, Immunor partners with the Norwegian Defence Research Establishment (FFI) and the Hylleraas Centre of Excellence for Quantum Molecular Sciences at Tromso to propose a Quick Reaction Centre for Virus Identification and Fast Vaccine Design in face of future pandemic threats.
  • 24th April 2023. Immunor acquired rights to additional onco-viral antigen patent family
  • 15th May 2023. Immunor acquired of Bionor Holding AS and the 100% owned subsidiary Bionor Immuno AS.
  • 23rd May 2023. European Commission approved the European Defence Fund consortium application – ‘Resilience’, where Immunor is a beneficiary partner